Immix Biopharma Secures US FDA Breakthrough Therapy Designation for NXC-201
Thursday, January 29, 2026
Immix Biopharma has received Breakthrough Therapy Designation from the US Food and Drug Administration for NXC-201 for the treatment of relapsed or refractory AL amyloidosis.
The designation is intended to speed up the development and regulatory review of medicines for serious conditions where early clinical data suggest a meaningful improvement over existing treatment options.
The FDA decision is based on interim Phase 2 clinical data from the NEXICART-2 trial. These results were presented in an oral session at the American Society of Hematology annual meeting in December 2025.
NEXICART-2 is an ongoing multi-centre Phase 2 clinical trial in the US evaluating NXC-201 in patients with relapsed or refractory AL amyloidosis. The study has a registrational design and is expected to enrol around 40 patients.
AL amyloidosis is a serious condition in which the immune system produces toxic light chains that build up in organs such as the heart, kidneys and liver, leading to organ damage and, in severe cases, death. The number of patients in the US with relapsed or refractory disease is estimated to be increasing by about 12% each year, reaching nearly 38,500 patients by 2026.
NXC-201 is a BCMA-targeted CAR-T cell therapy designed to selectively activate the immune system and eliminate the source of toxic light chains. In addition to Breakthrough Therapy Designation, the therapy has also received Regenerative Medicine Advanced Therapy and Orphan Drug designations from the US FDA, as well as Orphan Drug designation from the European Medicines Agency.
Source: globenewswire.com
